



Mucosis to Present on Intranasal Respiratory Syncytial Virus Vaccine Candidate SynGEM® at BioCapital Europe

Groningen, the Netherlands, March 25, 2015 – Mucosis B.V., a clinical stage biotechnology company using a proprietary technology platform to develop next-generation needle-free human vaccines for infectious diseases, announces today that CEO, Tom Johnston, will present a Company update at [BioCapital Europe](#) in Amsterdam on March 26.

During the conference, Mucosis will present an update on lead product SynGem® and its progress towards human clinical trials. SynGem®, a needle-free intranasal vaccine for protection against Respiratory Syncytial Virus (RSV), is being developed using Mucosis' proprietary Mimopath® platform, which has established human proof-of-concept in influenza.

[Recently published independent data](#) has provided further evidence that mucosal vaccination should offer enhanced protection for RSV when compared with intramuscular administration of vaccines. Last November, [Mucosis presented preclinical SynGEM® data](#) on its unique and stable prefusion F form of the antigen at the 9th International Respiratory Syncytial Virus Symposium in South Africa.

Tom Johnston, CEO of Mucosis commented, "This is an exciting time for Mucosis as we progress towards a novel vaccine for RSV, a significant infection which takes over 200,000 lives worldwide every year. We are working to advance SynGEM® through the various clinical stages into an available solution for preventing this priority global public health burden. Our innovations in both the delivery mechanism and efficacy of mucosal vaccines for RSV are setting Mucosis apart in this competitive market."

BioCapital Europe is an annual invitation-only investment conference offering VCs and investors access to innovative and exciting biotech companies from Benelux and Europe. The event is sponsored and run by Life Science Partners, an experienced healthcare investor dedicated to transforming breakthrough research into healthcare benefits. Mucosis will join around 40 other emerging companies presenting at this premier life sciences event.

Mucosis will be presenting at 16:00 in Session Room 3: Burgomaster's Chamber.

-Ends-

Note for Editors

About Mucosis www.mucosis.com

Mucosis B.V. (Mucosis) is a clinical-stage biotechnology company using a proprietary technology platform to develop next-generation needle-free human vaccines for infectious diseases. Mucosis's investigational patient-friendly vaccines can be delivered via the nose or mouth to elicit a more natural immune response with a broader base of protection. The company is developing multiple programs for its clinical-stage proprietary Mimopath® platform vaccine technology for several routes of administration including those that provide additional mucosal protection, where over 90% of pathogens enter the human body.

Mucosis's lead product SynGEM®, a stabilized recombinant vaccine delivered intranasally to prevent respiratory syncytial virus (RSV) infection, will enter human proof-of-concept studies in 2016. The annual global burden of RSV illness is significant, with 33.8 million estimated new episodes of RSV-associated acute lower respiratory

infection (ALRI) worldwide in children under 5, and over 3.4 million hospital admissions associated with severe RSV disease. Global mortality was estimated at 253,500 deaths in 2010.

The company has also developed PneuGEM[®], a vaccine to prevent diseases caused by pneumococcal bacteria, and FluGEM[®], a vaccine against influenza. FluGEM[®] served as a successful proof of concept for the Mimopath[®] platform in human clinical testing.

Mucosis has raised over EUR 20m, with key investment partners including MedSciences, BioGeneration, NOM & UU Holdings. The company has strategic partnerships in US, Asia and the EU with organisations including the US National Institutes of Health, China-based Changchun BCHO Biotechnology co., and the Netherlands Enterprise Agency. Mucosis's management is highly experienced in the design, development and commercialisation of vaccines. Mucosis employs over 10 staff at its headquarters in Groningen, The Netherlands.

About BioCapital Europe www.biocapitaleurope.com

US Media Enquiries: Lazar Partners	ROW Media Enquiries: Instinctif Partners
Fern Lazar/Danielle Lewis +1.212.867.1762 mucosis@lazarpartners.com	Sue Charles/AUS: +61 (0) 466 924218 Daniel Gooch/UK: +44 (0) 20 7866 7905 Alex Bannister/UK: +44 (0) 20 7457 2825 mucosis@instinctif.com